CME-NEX Likely Clears in 4Q After U.K.’s Review Kicked Off
(Premium) – CME and NEX shouldn’t find any opposition from the U.K. Competition and Markets Authority (CMA) to clear their $5.4 billion deal. Minimal horizontal overlaps and the parties’ complementary businesses suggest the merger review should end with a phase-one approval by year-end.
Continue Reading